Media stories about Oxford Immunotec Global (NASDAQ:OXFD) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Oxford Immunotec Global earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.0770924946309 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
Get Oxford Immunotec Global alerts: Oxford Immunotec��s T-SPOT庐.TB Test Included in the World Health Organization��s First-Ever Essential Diagnostics List (nasdaq.com) Oxford Immunotec Announces Launch of the Accutix�� Brand (finance.yahoo.com) Oxford Immunotec Announces Launch of the Accutix(TM) Brand (finance.yahoo.com) Zacks: Analysts Expect Oxford Immunotec Global PLC (OXFD) Will Post Quarterly Sales of $28.55 Million (americanbankingnews.com) Oxford Immunotec’s T-SPOT庐.TB Test Included in the World Health Organization’s First-Ever Essential Diagnostics List (finance.yahoo.com)Shares of Oxford Immunotec Global opened at $14.23 on Monday, MarketBeat.com reports. The stock has a market capitalization of $368.29 million, a PE ratio of -10.46 and a beta of -0.33. The company has a quick ratio of 5.04, a current ratio of 5.60 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global has a 52-week low of $10.00 and a 52-week high of $19.51.
Oxford Immunotec Global (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, May 1st. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.05. The business had revenue of $21.37 million during the quarter, compared to analysts’ expectations of $20.96 million. Oxford Immunotec Global had a negative return on equity of 43.51% and a negative net margin of 34.13%. The company’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.36) EPS. equities research analysts expect that Oxford Immunotec Global will post -0.98 earnings per share for the current fiscal year.
OXFD has been the subject of a number of research reports. BidaskClub raised Oxford Immunotec Global from a “hold” rating to a “buy” rating in a research report on Saturday, May 5th. Zacks Investment Research raised Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Friday, March 9th. BTIG Research set a $19.00 price objective on Oxford Immunotec Global and gave the company a “buy” rating in a report on Tuesday, May 1st. Finally, ValuEngine raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $17.40.
In other news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $12.77, for a total value of $38,310.00. Following the completion of the transaction, the director now owns 18,000 shares of the company’s stock, valued at approximately $229,860. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.61% of the company’s stock.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
No comments:
Post a Comment